Community awareness and use of anti-Müllerian hormone testing in Australia: a population survey of women
Authors: Copp Tessa , Thompson Rachel , Doust Jenny , Hammarberg Karin , Peate Michelle , Lensen Sarah , Cvejic Erin , Lieberman Devora , Mol Ben W , McCaffery Kirsten J 
Published: June 2023

STUDY QUESTION

What is the anti-Mullerian hormone (AMH) test usage, awareness, and perceived reasons for testing in a representative community sample of women in Australia?

SUMMARY ANSWER

: Among women aged 18–55 years, 13% had heard about AMH testing and 7% had had an AMH test, with the top three reasons for testing including due to infertility investigations (51%), considering pregnancy and wanting to understand their chances (19%) or to find out if a medical condition had affected fertility (11%).

WHAT IS KNOWN ALREADY

The growing availability of direct-to-consumer AMH testing has raised concerns about overuse, however as most AMH tests are paid for privately by consumers, data on test usage is not publicly available.

STUDY DESIGN, SIZE, DURATION

National cross-sectional survey of 1773 women, conducted in January 2022.

PARTICIPANTS/MATERIALS, SETTING, METHODS

Females aged 18–55 years were recruited from the representative ‘Life in Australia’ probability-based population panel and completed the survey online or by telephone. Main outcome measures included if and how participants had heard about AMH testing, whether they had ever had an AMH test, main reason for testing and test access.

MAIN RESULTS AND THE ROLE OF CHANCE

Of the 2423 women who were invited 1773 responded (73% response rate). Of these, 229 (13%) had heard about AMH testing and 124 (7%) had had an AMH test. Testing rates were highest among those currently aged 35–39 years (14%) and associated with educational attainment. Almost all accessed the test through their general practitioner or fertility specialist. Reasons for testing were: part of an infertility investigation (51%), considering pregnancy and wanting to understand chances of conceiving (19%), finding out if a medical condition had affected fertility (11%), curiosity (9%), considering egg freezing (5%), and considering delaying pregnancy (2%).

LIMITATIONS, REASONS FOR CAUTION

Although the sample was large and mostly representative, it was over-represented by people holding a university degree and under-represented by people aged 18–24, however, we used weighted data where possible to account for this. All data were self-reported so there is a risk of recall bias. The number of survey items was also restricted, so the type of counselling women received prior to testing, reasons for declining an AMH test or test timing were not measured.

WIDER IMPLICATIONS OF THE FINDINGS

Whilst most women reported having an AMH test for appropriate reasons, about one third had it for reasons not supported by evidence. Public and clinician education about the lack of utility of AMH testing for women not undergoing infertility treatment is needed.

STUDY FUNDING/COMPETING INTEREST(S)

This project was supported by a National Health and Medical Research Council (NHMRC) Centre for Research Excellence grant (1104136) and Program grant (1113532). T.C. is supported by an NHMRC Emerging Leader Research Fellowship (2009419). B.W.M. reports research funding, consultancy and travel support from Merck. D.L. is the Medical Director of City Fertility NSW and reports consultancy for Organon, Ferring, Besins and Merck. The authors have no other competing interests.

TRIAL REGISTRATION NUMBER

N/A.